Cencora (NYSE:COR) Trading 9.1% Higher on Strong Earnings

Shares of Cencora, Inc. (NYSE:COR) were up 9.1% during mid-day trading on Thursday after the company announced better than expected quarterly earnings. The stock traded as high as $359.10 and last traded at $359.90. Approximately 383,655 shares were traded during trading, a decline of 68% from the average daily volume of 1,195,642 shares. The stock had previously closed at $329.97.

The company reported $4.08 EPS for the quarter, beating analysts’ consensus estimates of $4.04 by $0.04. Cencora had a return on equity of 227.15% and a net margin of 0.48%.The business had revenue of $85.93 billion during the quarter, compared to analyst estimates of $86.12 billion. During the same quarter in the prior year, the company posted $3.73 EPS. Cencora’s quarterly revenue was up 5.5% compared to the same quarter last year.

Cencora Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Monday, March 2nd. Stockholders of record on Friday, February 13th will be given a $0.60 dividend. This represents a $2.40 annualized dividend and a dividend yield of 0.7%. The ex-dividend date of this dividend is Friday, February 13th. Cencora’s dividend payout ratio (DPR) is currently 30.19%.

Cencora News Roundup

Here are the key news stories impacting Cencora this week:

• Positive Sentiment: Cencora beat on EPS and showed improving margins, with adjusted metrics and profit per share topping estimates — a sign the specialty medicines strategy is supporting profitability. Reuters: Cencora beats quarterly profit estimates
• Positive Sentiment: Management raised fiscal‑2026 operating income growth targets (11.5%–13.5%) and lifted the sales outlook while integrating the OneOncology acquisition, which supports medium‑term revenue and margin expansion expectations. MSN: Cencora outlines operating income growth while integrating OneOncology TipRanks: Completes OneOncology acquisition
• Positive Sentiment: Cencora completed the OneOncology acquisition, which management says will drive specialty oncology volume — a strategic growth catalyst. BusinessWire: Q1 results / OneOncology
• Neutral Sentiment: The board declared a $0.60 quarterly dividend (ex‑dividend Feb 13), a modest yield that signals confidence but is unlikely to move the stock materially.
• Neutral Sentiment: Revenue was up 5.5% year‑over‑year to $85.9B, showing underlying growth despite the near‑term noise; full earnings call transcript and slide deck are available for details. Seeking Alpha: Earnings call transcript
• Negative Sentiment: Revenue missed Street estimates by a small margin (~$86.12B expected vs. $85.9B reported); the top‑line miss triggered intra‑day selling and headlines emphasizing a revenue shortfall. MSN: Revenue miss MarketWatch: Falls on revenue miss
• Negative Sentiment: The stock underperformed peers in trading after results, suggesting investors favored cleaner top‑line beats across the sector and rotated away from even slight misses. MSN: Underperformance vs competitors
• Negative Sentiment: Market reaction reflects focus on near‑term revenue execution despite positive guidance — if upcoming quarters don’t show clear sales acceleration, sentiment could remain weak. Benzinga: Lifts sales outlook despite revenue miss

Analysts Set New Price Targets

Several analysts have commented on COR shares. Barclays started coverage on shares of Cencora in a report on Monday, December 8th. They issued an “overweight” rating and a $400.00 price objective for the company. Mizuho raised their target price on Cencora from $340.00 to $380.00 and gave the company an “outperform” rating in a research note on Thursday, November 6th. Wall Street Zen cut Cencora from a “buy” rating to a “hold” rating in a research note on Friday, November 28th. Jefferies Financial Group upgraded Cencora from an “underperform” rating to a “buy” rating in a report on Thursday, January 22nd. Finally, Robert W. Baird set a $415.00 target price on shares of Cencora in a report on Tuesday, January 13th. One investment analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating and three have assigned a Hold rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $394.75.

Insider Activity at Cencora

In related news, EVP Silvana Battaglia sold 1,677 shares of the firm’s stock in a transaction that occurred on Friday, December 19th. The shares were sold at an average price of $345.00, for a total transaction of $578,565.00. Following the completion of the sale, the executive vice president owned 18,796 shares of the company’s stock, valued at $6,484,620. This trade represents a 8.19% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Robert P. Mauch sold 5,096 shares of the business’s stock in a transaction that occurred on Tuesday, January 20th. The stock was sold at an average price of $354.73, for a total transaction of $1,807,704.08. Following the completion of the transaction, the chief executive officer owned 66,726 shares of the company’s stock, valued at approximately $23,669,713.98. The trade was a 7.10% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last ninety days, insiders have sold 20,316 shares of company stock valued at $7,151,265. 0.38% of the stock is owned by insiders.

Institutional Inflows and Outflows

Several hedge funds have recently modified their holdings of COR. Mirae Asset Global Investments Co. Ltd. raised its holdings in Cencora by 13.0% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 48,270 shares of the company’s stock worth $15,086,000 after purchasing an additional 5,543 shares in the last quarter. Acadian Asset Management LLC raised its stake in shares of Cencora by 947.5% during the 2nd quarter. Acadian Asset Management LLC now owns 257,082 shares of the company’s stock worth $77,069,000 after acquiring an additional 232,539 shares in the last quarter. Mediolanum International Funds Ltd lifted its position in Cencora by 133.0% during the third quarter. Mediolanum International Funds Ltd now owns 56,293 shares of the company’s stock valued at $17,342,000 after acquiring an additional 32,138 shares during the last quarter. Segment Wealth Management LLC purchased a new position in Cencora in the third quarter worth $4,830,000. Finally, Synergy Asset Management LLC purchased a new stake in shares of Cencora during the 3rd quarter valued at $10,093,000. Hedge funds and other institutional investors own 97.52% of the company’s stock.

Cencora Trading Up 9.5%

The company has a 50 day moving average of $346.43 and a two-hundred day moving average of $325.27. The company has a debt-to-equity ratio of 4.32, a quick ratio of 0.55 and a current ratio of 0.90. The stock has a market capitalization of $70.07 billion, a PE ratio of 45.40, a P/E/G ratio of 1.72 and a beta of 0.68.

Cencora Company Profile

Cencora (NYSE:COR) is a global healthcare services and pharmaceutical distribution company that provides end-to-end solutions across the pharmaceutical supply chain. The company’s core activities include wholesale drug distribution, specialty drug distribution, and the operation of specialty pharmacies, complemented by logistics, cold-chain management and other fulfillment services designed to support complex and temperature-sensitive therapies.

Beyond physical distribution, Cencora offers a range of commercial and patient-focused services for pharmaceutical manufacturers and healthcare providers.